340 related articles for article (PubMed ID: 11970762)
21. The role of mitoxantrone in non-Hodgkin's lymphoma.
Armitage JO
Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Tarella C; Caracciolo D; Corradini P; Zallio F; Ladetto M; Cuttica A; Rossi G; Novero D; Gavarotti P; Pileri A
Leukemia; 2000 Apr; 14(4):740-7. PubMed ID: 10764164
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
Foussard C; Colombat P; Maisonneuve H; Berthou C; Gressin R; Rousselet MC; Rachieru P; Pignon B; Mahé B; Ghandour C; Desablens B; Casassus P; Lamy T; Delwail V; Deconinck E
Ann Oncol; 2005 Mar; 16(3):466-72. PubMed ID: 15695500
[TBL] [Abstract][Full Text] [Related]
28. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
29. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Velasquez WS; Lew D; Grogan TM; Spiridonidis CH; Balcerzak SP; Dakhil SR; Miller TP; Lanier KS; Chapman RA; Fisher RI;
J Clin Oncol; 2003 May; 21(10):1996-2003. PubMed ID: 12743154
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI
Blood; 2003 Sep; 102(5):1606-12. PubMed ID: 12738671
[TBL] [Abstract][Full Text] [Related]
32. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
33. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
35. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
36. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide.
Balzarotti M; Spina M; Sarina B; Magagnoli M; Castagna L; Milan I; Ripa C; Latteri F; Bernardi D; Bertuzzi A; Nozza A; Roncalli M; Morenghi E; Tirelli U; Santoro A
Ann Oncol; 2002 Sep; 13(9):1341-6. PubMed ID: 12196358
[TBL] [Abstract][Full Text] [Related]
37. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Burton C; Linch D; Hoskin P; Milligan D; Dyer MJ; Hancock B; Mouncey P; Smith P; Qian W; MacLennan K; Jack A; Webb A; Cunningham D
Br J Cancer; 2006 Mar; 94(6):806-13. PubMed ID: 16508640
[TBL] [Abstract][Full Text] [Related]
38. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Rodriguez J; McLaughlin P; Hagemeister FB; Fayad L; Rodriguez MA; Santiago M; Hess M; Romaguera J; Cabanillas F
Blood; 1999 Apr; 93(7):2202-7. PubMed ID: 10090928
[TBL] [Abstract][Full Text] [Related]
39. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
40. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
Armitage JO
Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
